Candel Therapeutics Advances Gene-Based Prostate Cancer Trial With New Biomarker Update
Candel Therapeutics, Inc. (CADL) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview
Candel Therapeutics is running a Phase 2a biomarker study in men with localized, favorable intermediate-risk prostate cancer, officially titled “A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec.” The goal is to see how the company’s gene-based therapy behaves in the body and how it affects key disease markers when added to standard external beam radiation therapy. The significance for investors is that these data may clarify the drug’s potential role in earlier-stage prostate cancer and support the broader platform value of Candel’s viral immunotherapy approach.
Intervention/Treatment
The study tests aglatimagene besadenovec, also known as CAN-2409, given with the oral antiviral valacyclovir. This is a biological, gene-directed therapy designed to activate the immune system against cancer cells when used with a companion prodrug. In this trial, men receive three injections of the therapy into the prostate, followed by 14-day courses of valacyclovir, alongside planned radiation treatment.
Study Design
This is an interventional, single-arm study, meaning all participants receive the same experimental treatment and there is no control group. Allocation is not randomized, and the trial is open-label, so both doctors and patients know what is being given. The primary aim is basic science: to track how the therapy spreads and to measure biomarker changes rather than to prove a direct clinical benefit such as survival at this stage.
Study Timeline
The study was first submitted to the registry on December 17, 2025, marking the formal launch of this program in localized prostate cancer. It is currently listed as recruiting, indicating that patient enrollment is underway but not yet complete. The most recent update on February 4, 2026, signals active trial management and refreshed information for investors and researchers. Primary completion and final completion dates are not yet reported but will be key future catalysts once biomarker and safety data are locked and analyzed.
Market Implications
For Candel Therapeutics (CADL), progress in this trial supports the company’s strategy to position CAN-2409 as a platform asset across multiple solid tumors, not only in advanced disease but also earlier in the treatment course. Any future positive biomarker readouts, such as evidence of immune activation or favorable interaction with radiation, could enhance confidence in the technology and fuel speculative interest in the stock. However, as a small Phase 2a biomarker study without direct efficacy endpoints, near-term price impact may be modest and driven more by sentiment than by fundamentals. Investors should also view this within the broader prostate cancer landscape, where larger players in radiotherapy, hormone therapy, and next-generation targeted treatments set a high bar for clinical and commercial differentiation. Still, credible signals from this study could make Candel a more attractive partner or acquisition target in the immuno-oncology space.
The study is currently ongoing and updated, with further details available on the ClinicalTrials portal.
To learn more about CADL’s potential, visit the Candel Therapeutics, Inc. drug pipeline page.
